Case Series: Simultaneous Use of Long-Acting Injectable Antipsychotics and Vivitrol or Long-Acting Buprenorphine in Dual Diagnosis Patients with Bipolar Disorder and Substance Use Disorders - PubMed
3 hours ago
- #substance use disorders
- #bipolar disorder
- #long-acting injectable antipsychotics
- Study evaluates concurrent use of long-acting injectable (LAI) antipsychotics with LAI naltrexone (Vivitrol) or buprenorphine (Sublocade) in patients with bipolar disorder and substance use disorders.
- Retrospective chart review of three patients showed clinical improvement: one achieved sustained remission, two had reduced opioid use but persistent cocaine use in one case.
- No severe adverse effects were reported, and all patients received adjunctive acceptance and commitment therapy.
- Findings suggest feasibility and utility of dual LAI therapy, especially for patients with poor medication adherence, warranting further controlled research.